RhEPO improves time to exhaustion by non-hematopoietic factors in humans

Autor: Simon Annaheim, Christian Breymann, Urs Boutellier, Markus Rehm, Matthias Jacob, Alexander Krafft
Rok vydání: 2016
Předmět:
Zdroj: European Journal of Applied Physiology. 116:623-633
ISSN: 1439-6327
1439-6319
DOI: 10.1007/s00421-015-3322-6
Popis: Erythropoietin (EPO) controls red cell volume (RCV) and plasma volume (PV). Therefore, injecting recombinant human EPO (rhEPO) increases RCV and most likely reduces PV. RhEPO-induced endurance improvements are explained by an increase in blood oxygen (O2) transport capacity, which increases maximum O2 uptake ( $$\dot{V}$$ O2max). However, it is debatable whether increased RCV or $$\dot{V}$$ O2max are the main reasons for the prolongation of the time to exhaustion (t lim) at submaximal intensity. We hypothesized that high rhEPO doses in particular contracts PV such that the improvement in t lim is not as strong as at lower doses while $$\dot{V}$$ O2max increases in a dose-dependent manner. We investigated the effects of different doses of rhEPO given during 4 weeks [placebo (P), low (L), medium (M), and high (H) dosage] on RCV, PV, $$\dot{V}$$ O2max and t lim in 40 subjects. While RCV increased in a dose-dependent manner, PV decreased independent of the rhEPO dose. The improvements in t lim (P +21.4 ± 23.8 %; L +16.7 ± 29.8 %; M +44.8 ± 62.7 %; H +69.7 ± 73.4 %) depended on the applied doses (R 2 = 0.89) and clearly exceeded the dose-independent $$\dot{V}$$ O2max increases (P −1.7 ± 3.2 %; L +2.6 ± 6.8 %; M +5.7 ± 5.1 %; H +5.6 ± 4.3 %) after 4 weeks of rhEPO administration. Furthermore, the absolute t lim was not related (R 2 ≈ 0) to RCV or to $$\dot{V}$$ O2max. We conclude that a contraction in PV does not negatively affect t lim and that rhEPO improves t lim by additional, non-hematopoietic factors.
Databáze: OpenAIRE
Externí odkaz: